

AUDITED (CONSOLIDATED) FINANCIAL RESULTS FOR THE THREE MONTHS AND YEAR ENDED 31st MARCH 2019

Prepared in compliance with the Indian Accounting Standards (Ind - AS)

| | Particulars | Three Months ended | | | Financial Year | Financial Year |
|--------------|--|--------------------|------------------|------------------|------------------|------------------|
| | | 31.03.2019 | 31.12.2018 | 31.03.2018 | Ended | Ended |
| | | (1) | (2) | (3) | (4) | (5) |
| | | (Audited) | (Unaudited) | (Audited) | (Audited) | (Audited) |
| INR in lakhs | | | | | | |
| | Income: | | | | | |
| I | Revenue from operations | 18,733.97 | 15,902.83 | 14,341.08 | 64,869.09 | 53,984.20 |
| II | Other income | 266.67 | 773.97 | 289.86 | 1,902.89 | 1,266.52 |
| III | Total Income (I+II) | 19,000.64 | 16,676.80 | 14,630.94 | 66,771.98 | 55,250.72 |
| | Expenses: | | | | | |
| IV | a. Cost of materials consumed | 2,378.79 | 2,467.83 | 2,079.47 | 9,511.76 | 9,021.63 |
| | b. Purchase of traded goods | 6,873.64 | 4,668.96 | 4,406.01 | 20,373.31 | 15,035.10 |
| | c. Changes in inventories of finished goods, stock in trade and work in progress | (632.47) | (314.95) | (266.80) | (1,007.04) | (238.77) |
| | d. Employee benefit expenses | 1,241.84 | 1,170.61 | 1,013.94 | 4,710.97 | 3,914.27 |
| | e. Finance cost | 1.36 | 1.47 | 1.36 | 6.00 | 6.12 |
| | f. Depreciation & Amortisation Expenses | 671.94 | 567.39 | 617.57 | 2,342.50 | 1,899.50 |
| | g. Other Expenses | 2,396.31 | 2,134.56 | 2,236.57 | 8,146.86 | 6,775.04 |
| | h. Total Expenses | 12,931.41 | 10,695.87 | 10,088.12 | 44,084.36 | 36,412.89 |
| V | Profit before exceptional items and Tax (III-IV) | 6,069.23 | 5,980.93 | 4,542.82 | 22,687.62 | 18,837.83 |
| VI | Exceptional items | - | - | - | - | - |
| VII | Profit Before Tax (V-VI) | 6,069.23 | 5,980.93 | 4,542.82 | 22,687.62 | 18,837.83 |
| VIII | Tax Expenses | | | | | |
| | (1) Current Tax | 1,962.84 | 1,427.66 | 1,014.43 | 5,485.70 | 4,054.91 |
| | (2) Deferred Tax | -879.22 | (27.47) | (0.94) | (453.62) | 319.42 |
| | Total Tax Expenses | 1,083.62 | 1,400.19 | 1,013.49 | 5,032.08 | 4,374.33 |
| IX | Net Profit for the Year (VII - VIII) | 4,985.61 | 4,580.75 | 3,529.33 | 17,655.54 | 14,463.50 |
| X | Other Comprehensive Income - Net of Income Tax | | | | | |
| | A. Items that will not be re-classified to profit or loss | | | | | |
| | i) Remeasurements of Defined Benefit Plan | (101.30) | (20.02) | 64.23 | (84.43) | 76.60 |
| | B. Items that will be re-classified to profit or loss | | | | | |
| | i) Exchange difference in translating the financial statements of foreign operations | (331.45) | 91.86 | - | 58.86 | 110.34 |
| XI | Total Comprehensive Income For The Year (IX + X) | 4,552.87 | 4,652.59 | 3,593.56 | 17,629.97 | 14,650.44 |
| XII | Profit attributable to: | | | | | |
| | Owners of the Company | 4,980.59 | 4,582.57 | 3,535.78 | 17,656.70 | 14,478.77 |
| | Non- controlling interests | 5.02 | (1.82) | (6.45) | (1.16) | (15.27) |
| | | 4,985.61 | 4,580.75 | 3,529.33 | 17,655.54 | 14,463.50 |
| XIII | Total Comprehensive Income For The Year attributable to | | | | | |
| | Owners of the Company | 4,547.83 | 4,654.42 | 3,600.01 | 17,631.13 | 14,665.71 |
| | Non- controlling interests | 5.02 | (1.82) | (6.45) | (1.16) | (15.27) |
| | | 4,552.87 | 4,652.59 | 3,593.56 | 17,629.97 | 14,650.44 |
| XIV | Paid up Equity Share Capital (Face value of share of Rs 2/- each) | 1,512.61 | 1,512.07 | 1,512.07 | 1,512.61 | 1,512.07 |
| XV | Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year | | | | | 34,871.08 |
| XVI | Earnings Per Share (EPS) (Not annualised) based on face value Rs 2/- per Equity share | | | | | |
| | (a) Basic (in Rupees) | 6.58 | 6.06 | 4.76 | 23.35 | 19.16 |
| | (b) Diluted (in Rupees) | 6.55 | 6.03 | 4.74 | 23.23 | 19.06 |



Indhan

Notes :

- 1) The above results have been prepared in accordance with the Companies (Indian Accounting standards) Rules, 2015 ("Ind As") prescribed under Section 133 of the Companies Act, 2013 and other accounting pronouncement generally accepted in India, to the extent applicable.
- 2) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary item.
- 3) The Board of Directors at their meeting held on 22nd May 2019, have recommended a final dividend of 10%, i.e Rs 2.20 per equity share of Rs 2/ each.

- 4) Ind AS 115 "Revenue from Contract with Customers" is mandatory for reporting periods beginning on or after April 1, 2018 and replaces the existing revenue recognition requirements. Based on management assessment, the adoption of the standard did not have any material impact on the financial results of the company.

- 5) Revenue from operations is disclosed net of Goods & Service Tax

- 6) The Consolidated financial results of the company have been reviewed and recommended by the Audit Committee of the Board and have been approved by the Board of Directors of the Company at their meeting held on 22nd May 2019.

- 7) Results for the year ended 31 March 2019 presented above have been audited by the statutory auditors of the Company. An unqualified opinion has been issued by them thereon.

- 8) The figures for the quarter ended 31st March 2019 and 31st March 2018 are the balancing amount between the audited figures in respect of the full financial year and the published unaudited year-to-date figures upto the end of the third quarter of the relevant Financial Year, which are subjected to limited review.

- 9) During the Quarter ended 31st March 2019, the Company had allotted 26,750 equity shares of Rs 2/- each under the Employee Stock Option Scheme 2015 and the total number of equity shares of the Company stands at 7,56,30,250 as on 31st March 2019.

- 10) Pursuant to the Business Transfer Agreement executed by the Company on 18th January, 2019, the regulated markets injectable business have been transferred to its wholly owned subsidiary company, Caplin Steriles Limited. The results of this subsidiary has been consolidated in the above results.


- 11) During the quarter ended 31st March 2019, the Company's subsidiary in El Salvador, namely Caplin Point El Salvador, S.A. DE C.V. has commenced its business operations. The results of this subsidiary has been consolidated in the above results.

- 12) During the quarter ended 31st March 2019, the results of the Company's Joint Venture entity namely Hainan Jointown Pharmaceutical Company Limited, China, in which the Company has 39% Stake, has been consolidated in the above results on proportionate basis.

- 13) During the Quarter ended 31st March 2019, Caplin Steriles Limited (Wholly owned subsidiary of the Company) has issued and allotted 3,59,22,993 Series A Compulsorily Convertible Preference Shares of face value of Rs.10/- at a premium of Rs.19.23/- each to M/s. Eight Roads Ventures India III LP carrying a coupon rate of 0.001% p.a. having a term of 19 years from the date of allotment.

- 14) Prior year / period figures are regrouped / rearranged wherever necessary.

Place: Chennai
Date: May 22, 2019


Dr Sridhar Ganesan
Managing Director



CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

AUDITED (STANDALONE) FINANCIAL RESULTS FOR THE THREE MONTHS AND YEAR ENDED 31st MARCH 2019

Prepared in compliance with the Indian Accounting Standards (Ind - AS)


| Particulars | Three Months Ended | | | Financial Year Ended | Financial Year Ended |
|---|--------------------|------------------|------------------|----------------------|----------------------|
| | 31.03.2019 | 31.12.2018 | 31.03.2018 | 31.03.2019 | 31.03.2018 |
| | (1) | (2) | (3) | (4) | (5) |
| | (Audited) | (Unaudited) | (Audited) | (Audited) | (Audited) |
| | INR In Lakhs | | | | |
| Income: | | | | | |
| I Revenue from operations | 14,074.32 | 13,976.17 | 11,044.13 | 53,690.57 | 42,657.39 |
| II Dividend from subsidiary | - | - | - | 1,648.24 | 1,139.50 |
| III Other income Including share of profit from subsidiary/LLP | 331.44 | 736.50 | 306.83 | 1,891.89 | 1,191.83 |
| IV Total Income (I+II+III) | 14,405.76 | 14,712.67 | 11,350.96 | 57,230.70 | 44,988.72 |
| V Expenses: | | | | | |
| a. Cost of materials consumed | 2,271.37 | 2,467.83 | 2,079.47 | 9,404.33 | 9,021.63 |
| b. Purchase of traded goods | 3,807.48 | 3,793.02 | 2,642.13 | 14,549.56 | 9,228.22 |
| c. Changes in inventories of finished goods, stock in trade and work in progress | 123.96 | (314.95) | (266.80) | (250.61) | (238.77) |
| d. Employee benefit expenses | 758.18 | 1,168.48 | 981.71 | 4,201.25 | 3,882.04 |
| e. Finance cost | 1.34 | 1.47 | 1.36 | 5.98 | 6.12 |
| f. Depreciation & Amortisation Expenses | 415.87 | 566.63 | 617.41 | 2,084.32 | 1,898.78 |
| g. Other Expenses | 1,494.47 | 1,944.13 | 2,124.50 | 6,970.49 | 6,585.40 |
| h. Total Expenses | 8,872.67 | 9,626.61 | 8,179.78 | 36,965.32 | 30,383.42 |
| VI Profit before exceptional items and Tax (IV-V) | 5,533.09 | 5,086.06 | 3,171.18 | 20,265.38 | 14,605.30 |
| VII Exceptional items | - | - | - | - | - |
| VIII Profit Before Tax (VI-VII) | 5,533.09 | 5,086.06 | 3,171.18 | 20,265.38 | 14,605.30 |
| IX Tax Expenses | | | | | |
| (1) Current Tax | 1,888.12 | 1,427.66 | 1,014.31 | 5,410.63 | 4,054.79 |
| (2) Deferred Tax | (387.50) | (27.47) | (0.94) | 38.10 | 319.42 |
| Total Tax Expenses | 1,500.63 | 1,400.19 | 1,013.37 | 5,448.73 | 4,374.21 |
| X Net Profit for the Year (VIII-IX) | 4,032.46 | 3,685.88 | 2,157.81 | 14,816.65 | 10,231.09 |
| XI Other Comprehensive Income/ (Loss) - Net of Income Tax | | | | | |
| A. Items that will not be re-classified to profit or loss | | | | | |
| i) Remeasurements of Defined Benefit Plan | (88.80) | (20.02) | 64.23 | (71.93) | 76.60 |
| XII Total Comprehensive Income For The Year (X+XI) | 3,943.67 | 3,665.86 | 2,222.04 | 14,744.72 | 10,307.69 |
| XIII Paid up Equity Share Capital (Face value of shares of Rs 2/- each) | 1,512.61 | 1,512.07 | 1,512.07 | 1,512.61 | 1,512.07 |
| XIV Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year | | | | | 28,048.36 |
| XV Earnings Per Share (EPS) (Not annualised) based on face value Rs 2/- per Equity share | | | | | |
| (a) Basic (in Rupees) | 5.34 | 4.88 | 2.94 | 19.60 | 13.54 |
| (b) Diluted (in Rupees) | 5.31 | 4.85 | 2.93 | 19.50 | 13.47 |



Notes :

- 1) The above results have been prepared in accordance with the Companies (Indian Accounting standards) Rules, 2015 ("Ind As") prescribed under Section 133 of the Companies Act, 2013 and other accounting pronouncement generally accepted in India, to the extent applicable.
- 2) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary item.
- 3) The Board of Directors at their meeting held on 22nd May 2019, have recommended a final dividend of 110%, i.e Rs 2.20 per equity share of Rs 2/ each.
- 4) Ind AS 115 "Revenue from Contract with Customers" is mandatory for reporting periods beginning on or after April 1, 2018 and replaces the existing revenue recognition requirements. Based on management assessment, the adoption of the standard did not have any material impact to the financial results of the company.
- 5) Revenue from operations is disclosed net of Goods and Service Tax
- 6) The standalone financial results of the company have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their meeting held on 22nd May 2019.
- 7) Results for the year ended 31 March 2019 presented above have been audited by the statutory auditors of the Company. An unqualified opinion has been issued by them thereon.
- 8) The figures for the quarter ended 31st March 2019 and 31st March 2018 are the balancing numbers between the audited figures in respect of the full financial year and the published unaudited year-to-date figures upto the end of the third quarter of the relevant Financial Year, which are subjected to limited review.
- 9) During the Quarter ended 31st March 2019, the Company had allotted 26,750 equity shares of Rs 2/- each under the Employee Stock Option Scheme 2015 and the total number of equity shares of the Company stands at 7,56,30,250 as on 31st March 2019.
- 10) Pursuant to the Business Transfer Agreement executed by the Company on 18th January, 2019, the regulated markets injectable business (including USFDA approved injectable plant and DSIR recognized R&D Units CP4 & CP5) have been transferred to its wholly owned subsidiary company, Caplin Steriles Limited for which the Company has been issued 9,32,99,752 equity shares of Rs.10/-each fully paid up as a consideration for this Slump Sale. Hence the results of the current quarter and year ended 31st March, 2019 are not comparable with the corresponding previous periods / previous quarter
- 11) Prior year / period figures are regrouped / rearranged wherever necessary.

Place: Chennai
Date: May 22, 2019


Dr Sridhar Ganesan
Managing Director

